Ilhan Ilker Avci1, Irfan Sahin2, Baris Gungor1, Suat Hayri Kücük3, Serhat Sigirci4, Sinan Varol2, Sevil Tugrul2, Adem Atici5, Orhan İnce2, Ertugrul Okuyan2. 1. Department of Cardiology, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital. 2. Department of Cardiology. 3. Department of Biochemistry, Bagcilar Training and Research Hospital. 4. Department of Cardiology, Şişli Hamidiye Etfal Training and Research Hospital. 5. Department of Cardiology, Medeniyet Üniversitesi Göztepe Etfal Training and Research Hospital, Istanbul, Turkey.
Abstract
BACKGROUND: Correlations between increased copeptin levels and various cardiovascular diseases have been described. In this study, we aimed to investigate the correlation between increased copeptin levels and paroxysmal atrial fibrillation (PAF) in rheumatic mitral stenosis (MS). METHODS: Patients with mild/moderate rheumatic MS and sinus rhythm were consecutively recruited from an echocardiography laboratory. Patients with a history of PAF and those with PAF on 24-48-hour ambulatory electrocardiography (ECG) monitoring constituted the study group, and those without PAF on ambulatory ECG monitoring constituted the control group. Clinical characteristics, echocardiographic parameters and levels of copeptin, plasma N-terminal proBNP (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) were evaluated. RESULTS: Twenty-nine patients with PAF and 124 control MS patients were studied. Patients in the PAF group were older, but the mitral valve areas and transmitral gradients were not different between the groups. In the PAF group, hs-CRP (1.2 vs. 0.8 mg/L, p < 0.001), NT-proBNP (335 vs. 115 pg/mL, p < 0.001) and copeptin (6.9 vs. 4.0 pmol/L, p < 0.001) levels were significantly higher than in the control group. Multivariable logistic regression analysis revealed that age [odds ratio (OR) 1.19, 95% confidence interval (CI) 1.04-1.38; p = 0.024], left atrial volume index (OR 1.23, 95% CI 1.06-1.41; p = 0.032), copeptin levels (OR 2.81, 95% CI 1.30-5.29; p < 0.001) and hs-CRP levels (OR 15.5, 95% CI 1.41-71.5; p = 0.012) were independent predictors of PAF. CONCLUSIONS: In patients with mild/moderate rheumatic MS, higher copeptin and hs-CRP levels predicted a higher risk of developing atrial fibrillation.
BACKGROUND: Correlations between increased copeptin levels and various cardiovascular diseases have been described. In this study, we aimed to investigate the correlation between increased copeptin levels and paroxysmal atrial fibrillation (PAF) in rheumatic mitral stenosis (MS). METHODS: Patients with mild/moderate rheumatic MS and sinus rhythm were consecutively recruited from an echocardiography laboratory. Patients with a history of PAF and those with PAF on 24-48-hour ambulatory electrocardiography (ECG) monitoring constituted the study group, and those without PAF on ambulatory ECG monitoring constituted the control group. Clinical characteristics, echocardiographic parameters and levels of copeptin, plasma N-terminal proBNP (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) were evaluated. RESULTS: Twenty-nine patients with PAF and 124 control MS patients were studied. Patients in the PAF group were older, but the mitral valve areas and transmitral gradients were not different between the groups. In the PAF group, hs-CRP (1.2 vs. 0.8 mg/L, p < 0.001), NT-proBNP (335 vs. 115 pg/mL, p < 0.001) and copeptin (6.9 vs. 4.0 pmol/L, p < 0.001) levels were significantly higher than in the control group. Multivariable logistic regression analysis revealed that age [odds ratio (OR) 1.19, 95% confidence interval (CI) 1.04-1.38; p = 0.024], left atrial volume index (OR 1.23, 95% CI 1.06-1.41; p = 0.032), copeptin levels (OR 2.81, 95% CI 1.30-5.29; p < 0.001) and hs-CRP levels (OR 15.5, 95% CI 1.41-71.5; p = 0.012) were independent predictors of PAF. CONCLUSIONS: In patients with mild/moderate rheumatic MS, higher copeptin and hs-CRP levels predicted a higher risk of developing atrial fibrillation.
Authors: M Katan; N Nigro; F Fluri; P Schuetz; N G Morgenthaler; F Jax; S Meckel; A Gass; R Bingisser; A Steck; L Kappos; S Engelter; B Müller; M Christ-Crain Journal: Neurology Date: 2011-01-12 Impact factor: 9.910
Authors: Tatiana Raskovalova; Raphael Twerenbold; Paul O Collinson; Till Keller; Hélène Bouvaist; Christian Folli; Davide Giavarina; Ulrich Lotze; Kai M Eggers; Anne-Marie Dupuy; Camille Chenevier-Gobeaux; Christophe Meune; Alan Maisel; Christian Mueller; José Labarère Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-11-20
Authors: Renate B Schnabel; Philipp S Wild; Sandra Wilde; Francisco M Ojeda; Andreas Schulz; Tanja Zeller; Christoph R Sinning; Jan Kunde; Karl J Lackner; Thomas Munzel; Stefan Blankenberg Journal: PLoS One Date: 2014-11-17 Impact factor: 3.240
Authors: Stefan Greisenegger; Helen C Segal; Annette I Burgess; Debbie L Poole; Ziyah Mehta; Peter M Rothwell Journal: Stroke Date: 2015-10-08 Impact factor: 7.914
Authors: Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983